SAREPTA THERAPEUTICS, INC. Payments of Debt Issuance Costs
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payments of Debt Issuance Costs of $17.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-12-31 was $4.27M.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2022-12-31 was $554.00K.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2025 was $17.06M.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2024 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2022 was $716.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $17.06M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $12.79M 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-01 | |||
| 2022-12-31 | $554.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $716.00K 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $162.00K 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | $39.00K 10-K · filed 2021-03-01 | ||
| 2019-12-31 | $689.00K 10-K · filed 2022-03-01 | |||
| 2017-12-31 | $15.15M 10-K · filed 2020-02-26 | |||
| 2015-12-31 | $399.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |